For most patients, a severe case of pneumonia is treated as an acute emergency: stabilize the breathing, start antibiotics, support the immune system, and send the patient home. A new study from the University of Gothenburg suggests that for a substantial share of adults, the episode may also be the first visible clue to something else entirely — an undiagnosed blood cancer or a weakened immune system that has gone unnoticed for years.
The research, published in the journal Scientific Reports, examined patients who developed invasive pneumococcal disease severe enough to require hospital care. The most common form of that illness is pneumonia, but the category also includes infections where pneumococcal bacteria invade normally sterile parts of the body, such as the bloodstream. According to the authors, these serious infections can function as an early warning signal that something is wrong with the immune system at a deeper level.
How the Study Was Designed
The team followed 156 individuals who developed invasive pneumococcal disease and needed hospital treatment in Region Västra Götaland, Sweden, between 2018 and 2023. The median age of the patients was 70 years, reflecting the fact that these infections disproportionately affect older adults. To establish a comparison, the researchers assembled a control group of 64 people matched by age and sex who had not experienced invasive pneumococcal disease.
Rather than looking only at the infection itself, the investigators turned their attention to the patients' immune systems. They measured antibody levels to assess immune function and tested for the presence of M protein, a well-known risk marker associated with blood cancer and with precursor conditions that can precede it. The goal was to determine whether a severe pneumococcal infection might serve as a practical trigger point for screening that is not currently part of standard care.
One in Four Carried a Marker for Blood Cancer
The results were striking. Among the patients in the pneumococcal disease group, one in four had M protein detectable in their blood. M protein can appear in people with blood cancer, but it can also be present in precursor states that do not always progress to malignancy — making its discovery a signal for careful follow-up rather than an automatic diagnosis.
That signal led to concrete clinical outcomes. Seven of the patients were ultimately diagnosed with blood cancer, while another 12 were found to have a condition that can, in some cases, develop into blood cancer. These findings were considerably less common among the individuals in the control group, who had not been hospitalized with invasive pneumococcal disease.
The pattern suggests that severe pneumococcal infection is not randomly distributed across the population. Instead, it may cluster among people whose immune defenses are already compromised by an underlying, unrecognized disease process.
Immunodeficiency and the Chance to Intervene
Blood cancer was not the only condition uncovered. Eight patients were found to have an immunodeficiency, a deficiency in the immune system's ability to mount an effective response. For seven of those eight, the discovery opened the door to preventive treatment aimed at reducing the risk of new, severe infections — an intervention that would likely never have been offered without the testing.
This is the practical argument at the heart of the study. Identifying an underlying immune problem or a blood disorder after a life-threatening infection does not simply label a patient; in many cases it changes their care. Preventive treatment, closer monitoring, and adjusted vaccination strategies can all follow from a diagnosis that might otherwise have waited years to surface.
Why Screening Is Not Yet Routine
Despite the findings, the tests that revealed these conditions are not typically ordered after a severe pneumococcal infection. That gap between what the data show and what happens in practice is what the researchers hope to close.
"Currently, these tests are not routinely performed after a severe pneumococcal infection. As a result, we may miss patients with undiagnosed blood cancer or immunodeficiency and therefore miss the opportunity to initiate treatment," said Tor Härnqvist, a doctoral student at the University of Gothenburg and an infectious disease physician at NU Hospital Group, who is one of the lead authors of the work.
The authors argue that screening for M proteins and antibody levels should be considered for adults who present with invasive pneumococcal disease. In their framing, the hospitalization becomes a rare and valuable window into a patient's underlying immune health — a chance to look beyond the immediate infection while the patient is already under close medical supervision.
Vaccination in a New Light
The study also points toward the importance of tailoring vaccinations for this population. Karin Bergman, a doctoral student in the same research group and an infectious disease physician at Södra Älvsborg Hospital, conducted the work as part of her doctoral thesis. For patients whose immune systems are impaired by an undiagnosed blood cancer or immunodeficiency, standard vaccination schedules may not produce the protective response clinicians assume, which makes understanding each patient's immune status all the more relevant to preventing the next severe infection.
The implication is that vaccination decisions for these patients may need to be individualized rather than delivered on a one-size-fits-all timetable, particularly once an immune defect has been identified.
What the Findings Mean in Practice
- Severe pneumococcal disease requiring hospitalization should be treated as a potential marker of underlying illness, not only as an isolated infection.
- Testing for M protein and antibody levels after such an infection could uncover blood cancers and precursor conditions that would otherwise remain hidden.
- Detecting an immunodeficiency allows clinicians to begin preventive treatment against future severe infections.
- Immune status may inform how vaccinations are selected and timed for affected patients.
- The findings come from a single Swedish region and describe an association, so broader confirmation is needed before screening becomes standard practice.
The study does not claim that every pneumonia patient has an underlying blood disorder — the majority did not. But it does reframe a familiar clinical event. A severe pneumococcal infection may be the moment when a silent immune problem finally becomes visible, and recognizing that possibility could shorten the path to diagnosis and treatment for patients who currently slip through the cracks.
This article is based on reporting by Medical Xpress. Read the original article.
Originally published on medicalxpress.com
